Herpes Zoster Ophthalmicus

Excerpt

Infection with the varicella-zoster virus (VZV) most often occurs in childhood and spreads through airborne, droplet, and contact transmission. Herpes zoster results from reactivation of latent VZV within a sensory nerve ganglion, often presenting decades after the initial infection. The disease typically manifests as a unilateral maculopapular or vesicular rash in a single dermatomal distribution. Herpes zoster ophthalmicus (HZO) occurs when the virus involves the ophthalmic division of the trigeminal cranial nerve. Although the diagnosis of HZO does not necessarily indicate ocular involvement, eye disease develops in approximately 50% of cases. Ocular manifestations may include conjunctivitis, uveitis, episcleritis, keratitis, and retinitis. Because of the high risk of vision loss if not promptly recognized and treated, HZO is considered an ophthalmologic emergency.

Herpes zoster ophthalmicus represents one of the most clinically significant forms of VZV reactivation, potentially devastatingly affecting the eye and visual system. Accounting for approximately 10% to 25% of all herpes zoster cases, HZO results from reactivation of dormant VZV in the ophthalmic branch of the trigeminal nerve and produces a wide range of cutaneous, ocular, and neurologic complications. Unlike herpes zoster confined to other dermatomes, HZO carries a disproportionately high morbidity, with both acute and chronic sequelae such as keratitis, uveitis, retinitis, optic neuropathy, and postherpetic neuralgia. The clinical burden of HZO extends beyond visual impairment to include chronic pain, diminished quality of life, and substantial socioeconomic consequences for patients and healthcare systems.

Globally, the incidence of herpes zoster increases with advancing age and immunosuppression, paralleling demographic shifts toward aging populations and higher prevalence of chronic diseases. In this context, HZO represents a growing public health concern. Epidemiological study results indicate that the lifetime risk of herpes zoster is nearly 30%, with approximately 1 in 3 individuals expected to develop shingles during their lifetime. Among these, nearly one-quarter will experience ophthalmic involvement, translating into millions of individuals at risk for HZO-related complications worldwide. Immunosenescence, HIV infection, malignancy, and immunosuppressive therapies further amplify susceptibility. Notably, while HZO predominantly affects older adults, cases are increasingly reported in younger, immunocompromised populations, underscoring its broad clinical relevance.

The pathophysiology of HZO reflects the complex interplay between viral latency, immune dysfunction, and neurotropism. Following primary varicella infection, VZV establishes latency in sensory ganglia, including the trigeminal ganglion. Reactivation occurs when cell-mediated immunity wanes, allowing the virus to replicate and travel to the ophthalmic dermatome along sensory axons. Clinically, this manifests as a painful vesicular rash over the forehead, eyelids, and nose (eg, the Hutchinson sign), often preceding or coinciding with ocular involvement (see Image. Herpes Zoster Ophthalmicus With Hutchinson Sign). Viral replication and subsequent inflammation within ocular tissues can produce keratitis, conjunctivitis, scleritis, or uveitis. In severe cases, posterior segment involvement such as acute retinal necrosis or optic neuritis may occur, threatening irreversible vision loss.

A defining feature of HZO is the broad spectrum of ocular complications. Corneal involvement is widespread, occurring in up to 65% of patients, and includes epithelial keratitis, stromal keratitis, and neurotrophic keratopathy. Chronic inflammation and scarring may lead to corneal opacification, thinning, and perforation. Anterior uveitis, often granulomatous, is another hallmark, which can be complicated by secondary glaucoma and cataract formation. Posterior segment complications, although less common, are vision-threatening and include necrotizing retinitis and vasculitis. Moreover, chronic corneal anesthesia and tear film dysfunction predispose patients to persistent epithelial defects and secondary infections, further compounding morbidity.

Beyond ocular pathology, HZO is strongly associated with postherpetic neuralgia, a chronic neuropathic pain syndrome resulting from VZV-induced damage to sensory nerves. PHN can persist for months to years, significantly impairing quality of life. The combination of vision loss and chronic pain creates a dual burden, with profound psychosocial and economic consequences. Patients with HZO often experience reduced productivity, higher healthcare utilization, and increased risk of depression and social isolation.

Despite advances in antiviral therapy, significant practice gaps persist in the timely recognition and management of HZO. Early initiation of systemic antiviral agents such as acyclovir, valacyclovir, or famciclovir—ideally within 72 hours of rash onset—is critical to limit viral replication, reduce ocular complications, and mitigate the risk of PHN. However, delayed presentation, misdiagnosis, and inconsistent adherence to treatment guidelines remain common. Furthermore, management of HZO often requires long-term surveillance and multidisciplinary input, including ophthalmologists, dermatologists, neurologists, and pain specialists. In many settings, fragmented care and a lack of interprofessional collaboration hinder optimal outcomes.

Vaccination represents a significant advance in the prevention of herpes zoster and HZO. The recombinant zoster vaccine has demonstrated over 90% efficacy in preventing shingles and its complications, even in older adults. Despite this, vaccine uptake remains suboptimal in many regions due to cost, access barriers, and lack of awareness. Expanding immunization coverage could substantially reduce the incidence of HZO and its associated complications, yet strategies for implementation require coordination between public health agencies, clinicians, and policymakers.

Emerging research continues to shed light on the immunological and molecular underpinnings of HZO. Advances in ocular imaging, such as anterior segment optical coherence tomography and in vivo confocal microscopy, are improving the detection and monitoring of corneal and anterior segment changes. Ongoing studies explore novel antivirals, immunomodulatory therapies, and regenerative approaches for neurotrophic keratopathy. The integration of these innovations into clinical practice has the potential to transform the management paradigm for HZO.

From an educational standpoint, a pressing need remains to bridge the gap between evidence-based best practices and real-world clinical care. Clinicians must be equipped to recognize the early signs of HZO and implement comprehensive management strategies that address both acute and chronic sequelae. Continuing education activities are critical in disseminating current evidence, fostering interprofessional collaboration, and enhancing clinician confidence in managing this complex condition.

This educational activity provides participants a thorough overview of herpes zoster ophthalmicus, including its epidemiology, risk factors, clinical features, complications, and management strategies. Learners gain insights into the importance of early antiviral therapy, adjunctive corticosteroid use, and methods for preventing and managing long-term complications such as neurotrophic keratopathy and postherpetic neuralgia. The activity also emphasizes the value of an interprofessional approach, highlighting how collaboration among ophthalmologists, primary care clinicians, dermatologists, neurologists, pharmacists, and pain specialists enhances patient care.

Ultimately, this educational activity aims to equip clinicians with the knowledge and skills to improve patient outcomes in HZO. By addressing current practice gaps, fostering interprofessional collaboration, and integrating emerging evidence into practice, this activity will help reduce the burden of vision loss and chronic pain associated with HZO. As the population ages and the incidence of herpes zoster rises, the need for effective education and training in managing HZO becomes ever more critical.